losartan has been researched along with Craniofacial Abnormalities in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Craniofacial Abnormalities: Congenital structural deformities, malformations, or other abnormalities of the cranium and facial bones.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osborn, MJ | 1 |
| Webber, BR | 1 |
| McElmurry, RT | 1 |
| Rudser, KD | 1 |
| DeFeo, AP | 1 |
| Muradian, M | 1 |
| Petryk, A | 1 |
| Hallgrimsson, B | 1 |
| Blazar, BR | 1 |
| Tolar, J | 1 |
| Braunlin, EA | 1 |
1 other study available for losartan and Craniofacial Abnormalities
| Article | Year |
|---|---|
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Topics: Angiotensin Receptor Antagonists; Animals; Craniofacial Abnormalities; Disease Models, Animal; Femal | 2017 |